Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Clin Exp Allergy ; 39(8): 1160-9, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19438590

ABSTRACT

BACKGROUND: Several risk factors for asthma have been identified in infants and young children with recurrent wheeze. However, published literature has reported contradictory findings regarding the underlying immunological mechanisms. OBJECTIVES: This study was designed to assess and compare the immunological status during the first 2 years in steroid-naive young children with >or= three episodes of physician-confirmed wheeze (n=50), with and without clinical risk factors for developing subsequent asthma (i.e. parental asthma or a personal history of eczema and/or two of the following: wheezing without colds, a personal history of allergic rhinitis and peripheral blood eosinophilia >4%), with age-matched healthy controls (n=30). METHODS: Peripheral blood CD4(+)CD25(+) and CD4(+)CD25(high) T cells and their cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), GITR and Foxp3 expression were analysed by flow cytometry. Cytokine (IFN-gamma, TGF-beta and IL-10), CTLA-4 and Foxp3 mRNA expression were evaluated (real-time PCR) after peripheral blood mononuclear cell stimulation with phorbol 12-myristate 13-acetate (PMA) (24 h) and house dust mite (HDM) extracts (7th day). RESULTS: Flow cytometry results showed a significant reduction in the absolute number of CD4(+)CD25(high) and the absolute and percentage numbers of CD4(+)CD25(+)CTLA-4(+) in wheezy children compared with healthy controls. Wheezy children at a high risk of developing asthma had a significantly lower absolute number of CD4(+)CD25(+) (P=0.01) and CD4(+)CD25(high) (P=0.04), compared with those at a low risk. After PMA stimulation, CTLA-4 (P=0.03) and Foxp3 (P=0.02) expression was diminished in wheezy children compared with the healthy children. After HDM stimulation, CTLA-4 (P=0.03) and IFN-gamma (P=0.04) expression was diminished in wheezy children compared with healthy children. High-risk children had lower expression of IFN-gamma (P=0.03) compared with low-risk and healthy children and lower expression of CTLA-4 (P=0.01) compared with healthy children. CONCLUSIONS: Although our findings suggest that some immunological parameters are impaired in children with recurrent wheeze, particularly with a high risk for asthma, further studies are needed in order to assess their potential as surrogate predictor factors for asthma in early life.


Subject(s)
Asthma/immunology , Cytokines/immunology , Respiratory Sounds/immunology , Animals , Antigens, CD/biosynthesis , Antigens, Dermatophagoides/immunology , CTLA-4 Antigen , Cytokines/genetics , Flow Cytometry , Humans , Infant , Interferon-gamma/biosynthesis , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Risk Factors , T-Lymphocytes, Regulatory/immunology , Tetradecanoylphorbol Acetate/pharmacology
3.
Acta Med Port ; 16(1): 41-6, 2003.
Article in Portuguese | MEDLINE | ID: mdl-12828005

ABSTRACT

Hyperreactive malarial splenomegaly is thought to represent an immunological dysfunction due to recurrent episodes of malaria. The authors present a case of hyperreactive malarial splenomegaly in a patient from São Tomé e Príncipe and discuss aspects of its differential diagnosis and treatment. A revision is made of recent concepts related to its pathogenesis and relationship with lymphoproliferative disorders. Malarial DNA was found in the absence of parasite forms in the peripheral blood. This may indicate that latent infection plays a role in its pathogenesis.


Subject(s)
Malaria/complications , Splenomegaly/diagnosis , DNA, Protozoan/blood , DNA, Protozoan/isolation & purification , Female , Humans , Lymphoproliferative Disorders/diagnosis , Lymphoproliferative Disorders/drug therapy , Malaria/pathology , Middle Aged , Recurrence , Splenomegaly/drug therapy
4.
Res Microbiol ; 152(6): 569-76, 2001.
Article in English | MEDLINE | ID: mdl-11501675

ABSTRACT

The novel tetraaza-macrocyclic compound 3,7,11-tris(carboxymethyl)-3,7,11,17-tetraaza-bicyclo[11.3.1]heptadeca-1(17),13,15-triene, abbreviated as ac3py14, was investigated for its activity against Mycobacterium tuberculosis and for induction of protective cellular immune responses. Perspective results show that ac3py14 and its Fe3+ 1:1 complex, [Fe(ac3py14)], inhibited radiometric growth of several strains of M. tuberculosis. Inhibition with 25 microg/mL varied from 99% for H37Rv to 80% and above for multiple drug-resistant clinical isolates. The capacity of ac3py14 to elicit a beneficial immune response without cellular apoptosis was assessed and compared to the effects of virulent M. tuberculosis. The present study produces evidence that after stimulation with ac3py14 there was significant production of interferon gamma (IFN-gamma), whereas the production of interleukin-5 (IL-5) remained low, and there was development of a memory population (CD45RO). The level of binding of Annexin V, a marker of apoptosis, was not sufficient to result in toxic effects toward alphabeta and gammadelta T cells and CD14+ macrophages. This preliminary study is the first report of a compound that simultaneously exerts an inhibitory effect against M. tuberculosis and induces factors associated with protective immune responses.


Subject(s)
Antitubercular Agents/pharmacology , Heterocyclic Compounds, 2-Ring/pharmacology , Mycobacterium tuberculosis/drug effects , Adult , Annexin A5/analysis , Antitubercular Agents/immunology , Apoptosis/drug effects , Cell Division/drug effects , Colony Count, Microbial , Drug Resistance, Microbial , Female , Humans , Interferon-gamma/analysis , Interferon-gamma/biosynthesis , Interleukin-5/analysis , Interleukin-5/biosynthesis , Leukocyte Common Antigens/biosynthesis , Leukocyte Common Antigens/immunology , Lymphocyte Activation/drug effects , Lymphocyte Activation/immunology , Macrophages/drug effects , Male , Mycobacterium tuberculosis/growth & development , Mycobacterium tuberculosis/immunology , Pilot Projects , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Tuberculosis/drug therapy , Tuberculosis/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...